Clear cell gynecologic malignancies do poorly with standard carbo/taxol, so it is encouraging a single-arm phase 2 trial revealed a durable response rate of 25% with second-line pembrolizumab, far outshining historic outcomes with second-line chemo. | Kristeleit, JAMA Oncol 2025
